Clinical Trials · NCT04302454
Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- University Medical Center Groningen
- Enrollment
- 280
- Start date
- Mar 2020
- Locations
- 13 sites, Netherlands
- Primary endpoint
- Metastases progression-free survival (MPFS)